Long-Term Anticoagulation in a Severe Hemophilia A Patient Receiving Efanesoctocog Alpha Prophylaxis: A Case Report

Laurent Sattler; Agathe Herb; Anne-Cécile Gerout; Stéphane Klein; Jordan Wimmer; Olivier Feugeas; Cécile Ronde-Oustau; Dominique Desprez

doi:10.1055/a-2689-3812

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost
DOI: 10.1055/a-2689-3812

Letter to the Editor

Long-Term Anticoagulation in a Severe Hemophilia A Patient Receiving Efanesoctocog Alpha Prophylaxis: A Case Report

Authors

Laurent Sattler

¹Laboratoire d'Hématologie, Unité Hémostase, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Agathe Herb

¹Laboratoire d'Hématologie, Unité Hémostase, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Anne-Cécile Gerout

²Service de Pharmacie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Stéphane Klein

³Service de Chirurgie Septique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Jordan Wimmer

¹Laboratoire d'Hématologie, Unité Hémostase, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Olivier Feugeas

⁴Centre de Ressource et Compétence des Maladies Hémorragiques Constitutionnelles, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Cécile Ronde-Oustau

³Service de Chirurgie Septique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Dominique Desprez

⁴Centre de Ressource et Compétence des Maladies Hémorragiques Constitutionnelles, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Abstract

Volltext

Referenzen

References
1 Canaro M, Goranova-Marinova V, Berntorp E. The ageing patient with haemophilia. Eur J Haematol 2015; 94 (Suppl. 77) 17-22
2 Hermans C. Thrombosis and hemophilia: little more evidence, much more guidance. HemaSphere 2023; 7 (06) e918
3 von Drygalski A, Chowdary P, Kulkarni R. et al; XTEND-1 Trial Group. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med 2023; 388 (04) 310-318
4 Keam SJ. Efanesoctocog alfa: First approval. Drugs 2023; 83 (07) 633-638
5 Konkle BA, Shapiro AD, Quon DV. et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020; 383 (11) 1018-1027
6 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
7 Srivastava A, Santagostino E, Dougall A. et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl. 06) 1-158
8 Pipe S, Sadeghi-Khomami A, Konkle BA. et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia 2024; 30 (01) 214-223
9 Société francaise d'anesthésie et de réanimation. [Perioperative management of chronic treatment and medical devices. Cardiovascular pathologies [In French]. Ann Fr Anesth Réanim 2009; 28 (12) 1037-1045
10 Toorop MMA, van Rein N, Nierman MC. et al. Inter- and intra-individual concentrations of direct oral anticoagulants: The KIDOAC study. J Thromb Haemost 2022; 20 (01) 92-103
11 Klamroth R, von Drygalski A, Hermans C. et al. Perioperative management with efanesoctocog alfa in patients with haemophilia A in the phase 3 XTEND-1 and XTEND-Kids studies. Haemophilia 2025; 31 (03) 391-400
12 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
13 Schutgens REG, Jimenez-Yuste V, Escobar M. et al. Antithrombotic treatment in patients with hemophilia: An EHA-ISTH-EAHAD-ESO Clinical Practice Guidance. HemaSphere 2023; 7 (06) e900
14 Nougier C, Pipe SW, Pabinger I. et al. Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab. J Thromb Haemost 2025; 23 (05) 1516-1521
15 Buffart B, Demulder A, Rozen L. Letter in Response to the Article “A Global Comparative Field Study to Evaluate the Factor VIII Activity of Efanesoctocog Alfa by One-Stage Clotting and Chromogenic Substrate Assays at Clinical Haemostasis Laboratories”. Haemophilia 2025; (e-pub ahead of print)
16 Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. Int J Lab Hematol 2019; 41 (02) 227-233